Business Wire

TXONE-NETWORKS

25.4.2024 09:05:30 CEST | Business Wire | Press release

Share
New CPS Protection Platform: TXOne Networks Presents SageOne in Hannover

TXOne Networks, a leading company in the field of cyber-physical systems (CPS) security, will be presenting its new CPS security platform during the Hannover Messe from 22nd to 26th April 2024 at stand B06 in hall 16: SageOne, which means Wise Man Number One. This central management console provides an overview of the CPS attack surface of the OT environment.

All three TXOne product lines can be centrally controlled, namely Stellar for endpoint protection, Element for security inspection and Edge for network defense. The platform offers integrated OT security across the entire lifecycle of the objects to be protected and enables reliable detection and response to threats.

SageOne essentially covers three main pillars:

  • CPS Attack Surface Management: Visibility is a cornerstone for cybersecurity. A clear view of the overall security posture helps identify security focal points in an OT environment. SageOne focuses on operational security by honing in on assets and illuminating the security information of various controls.
  • Integrated Lifecycle Protection: Centralized management simplifies cybersecurity governance and achieves collaborative defense. As an abstraction layer, SageOne streamlines the contextualization and consolidation of data across various products. It offers a tailored, task-oriented console designed specifically for executives, security personnel, and plant leaders.
  • CPS Threat Detection & Response: Properly handling known threats is absolutely crucial. Coping with unknown threats is equally important. SageOne compiles all security insights from multiple solutions and scouts for potential risks in order to enable early caution and response when needed.

To achieve this goal, the platform includes the following key components:

  • Threat intelligence means collecting, analysing and applying knowledge about potential and existing threats against a CPS. The TXOne Threat Research department carries out a large number of investigations into vulnerabilities in Industrial Control Systems (ICS) devices and protocols. It analyses malware and ransomware in connection with Operational Technology (OT) threats. This information can also come from a variety of other sources: Publicly available data, industry reports and private sector information.
  • Behaviour-based AI analytics engines use artificial intelligence to monitor and analyse the behaviour of users, devices and systems within a CPS. This advanced analytics engine learns the normal behavioural patterns of these entities and can detect unusual activity or anomalies that could indicate a security threat.
  • The Compliance Framework provides a structured approach to compliance with relevant safety standards and regulations. It includes policies, procedures and controls to ensure that every system complies with legal requirements, industry standards and security best practices.
  • The Data Visualiser is a tool that transforms complex safety data and metrics into an easy-to-understand visual form. Using diagrams, graphs and network maps, security professionals can recognise patterns and trends as well as anomalies more quickly.
  • The Ecosystem Integrator helps to seamlessly integrate different tools and technologies. This includes standardising data formats, promoting the interoperability of different systems and creating a coherent security architecture that covers the entire ecosystem. This enables security forces to obtain a standardised overview of the security situation, automate processes and respond more effectively to threats.

SageOne focuses on the analysis of unexpected behaviour and unknown threats. Suspicious events can be identified by comparing endpoint and network telemetry within the OT-native XDR (Extended Detection and Response) engine. The platform thus combines advanced technologies with a user-friendly interface to ensure the protection of critical infrastructures. To achieve reliable CPS attack surface management, SageOne also offers Asset Centric Visibility to provide full visibility of any device on the network. In addition, the analysis of the attack surface is prioritised and recommendations are made.

To enable a rapid response to threats, SageOne can issue early warnings of suspicious behaviour in the network as part of CPS Threat Detection & Response Orchestration using cross-telemetry analysis.

In addition, Integrated Lifecycle Protection protects devices and systems over their entire service life. The centralised management of the security solutions and the unified defence under one roof contribute to this, resulting in high cost efficiency. With SageOne, TXOne Networks emphasises its commitment to the security and reliability of CPS and continuously drives the development of OT security.

Visit TXOne Networks at the Hannover Messe from 22nd to 26th April 2024 at booth B06 in hall 16.

Follow TXOne Networks on the blog, Twitter and LinkedIn.

About TXOne Networks

TXOne Networks provides OT security products that ensure the reliability and security of industrial control systems and operational technology environments through the OT Zero Trust methodology. TXOne Networks works with both leading industrial manufacturers and critical infrastructure operators to develop practical and business-friendly approaches to OT defence. TXOne Networks offers both network and endpoint-based products to secure OT networks and mission-critical devices in real-time and with high security depth. www.txone.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240420367607/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye